Table 5.

RH (95% CI) of Death by Age and Among Women Who Maintained Their BMD or Experienced Accelerated Loss in BMD

	Total population		Exclude estrogen users		Women with ≥2 BMD measures
	RH	95% CI	RH	95% CI	RH	95% CI
Age alone (per 5-yr decrease)	0.55	(0.53–0.56)	0.55	(0.53–0.57)	0.54	(0.52–0.56)
Unadjusted models
Maintained	0.37	(0.32–0.43)	0.35	(0.30–0.42)	0.53	(0.47–0.59)
Accelerated	1.18	(1.08–1.28)	1.17	(1.07–1.28)	1.38	(1.25–1.52)
Age-adjusted models
Maintained	0.46	(0.40–0.53)	0.45	(0.38–0.53)	0.60	(0.54–0.67)
Accelerated	1.08	(0.99–1.17)	1.08	(0.99–1.18)	1.19	(1.07–1.31)
Age- and BMD-adjusted models
Maintained	0.46	(0.39–0.53)	0.44	(0.37–0.52)	0.60	(0.53–0.68)
Accelerated	1.06	(0.97–1.16)	1.07	(0.97–1.17)	1.20	(1.08–1.33)
Multivariate models*
Maintained	0.49	(0.42–0.58)	0.48	(0.40–0.58)	0.63	(0.56–0.72)
Accelerated	0.98	(0.89–1.08)	0.99	(0.89–1.09)	1.12	(1.00–1.25)
Multivariate models†
Maintained	0.53	(0.45–0.62)	0.53	(0.44–0.63)	0.66	(0.58–0.76)
Accelerated	0.95	(0.87–1.05)	0.97	(0.88–1.07)	1.10	(0.98–1.23)

The expected group forms the referent group.

* Adjusted for age, total hip BMD, current smoking, physical activity, weight change, hypertension, diabetes, calcium supplement use, health status, and any incident fracture over follow-up. MV models in total population also include estrogen use.

^† Multivariate models: additional adjustment for any estrogen, bisphosphonate, or SERM use after baseline.